Posters

      Analysis of inflammatory markers in adult Japanese smokers and non-smokers

      Martin Leroy, C.; Hasunuma, T.; Oey, J.; Lindner, D.; Haziza, C.; Peck, M.; Sandefur, M.; Magnette, J.

      Conference date
      Apr 25, 2009
      Conference name
      II Asthma & COPD Worl Forum
      Link to more information
      Topic
      Summary

      The most important risk factor for chronic obstructive pulmonary disease (COPD) is cigarette smoking, and it has been estimated that smoking accounts for up to 95% of COPD in the developed world. However, the precise mechanisms by which smoking causes COPD are unknown. An observational study has been performed to measure biomarkers of exposure (BoExp) to cigarette smoke and biomarkers of effect (BoEff) in adult Japanese smokers and non-smokers. The main purpose of this study was to determine the levels and variability of BoEff and to understand the effect of smoking on these biomarkers. For exploratory purposes, multiplex analysis of inflammatory biomarkers was performed in plasma of study participants. These results constitute the principal focus of this abstract. This study was conducted in 9 study centres in Japan, and was performed according to the principles of good clinical practice. The site locations were selected to cover a broad geographical range. This study included adult smokers and non-smokers 30 years of age and above in a ratio of 2:1 (smokers to non-smokers). Altogether, 1098 subjects (731 smokers and 367 non-smokers) were enrolled; data from 1077 of the subjects (716 smokers and 361 non-smokers) were analysed as part of the full analysis set. Plasma samples from two visits were analysed using multiplex technology (rules based medicine). The human map™ was used to simultaneously analyse 52 analytes in each sample. Statistical analysis indicated differences between adult smokers and non-smokers in the following biomarkers: α-1 antitrypsin, intracellular adhesion molecule-1 (ICAM-1), immunoglobulin A (IgA), macrophage-derived chemokine (MDC), matrix metalloproteinases 2 and 9 (MMP-2 and MMP-9), tumour necrosis factor rii (TNF R2), and vascular cell adhesion molecule-1 (VCAM 1). This analysis provides semi-quantitative information about biomarkers affected by cigarette smoking, some of which may be involved in the pathogenesis of COPD.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.